SCHEMBL31751270

SCHEMBL31751270

COC(=O)Cn1c(C)nc2ccc(Br)nc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ MAPT P10636 3/20 0.45
▸ POLB P06746 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ CASP3 P42574 1/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ HSD17B10 Q99714 4/20 0.40
▸ AKR1B10 O60218 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31750637 0.84 CYP1A2 (0.54) KDM4EALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL31750694 0.81 KDM4E (0.51) KDM4EALDH1A1HTTSMN1; SMN2NPC1
SCHEMBL18336768 0.79 KDM4E (0.39) KDM4EALDH1A1MAPTPOLBHTT
SCHEMBL31750717 0.77 KDM4E (0.46) KDM4EALDH1A1MAPTPOLBHTT
SCHEMBL31750804 0.77 POLB (0.49) KDM4EALDH1A1POLBSMN1; SMN2CASP3
SCHEMBL31752292 0.76 KDM4E (0.43) KDM4EALDH1A1MAPTPOLBHTT
SCHEMBL10085577 0.75 KDM4E (0.51) KDM4EALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL18337338 0.75 AADAT (0.45) POLBHTTSMN1; SMN2RAB9AKMT2A
SCHEMBL31750552 0.74 KDM4E (0.47) KDM4EALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL31750690 0.74 CYP1A2 (0.68) KDM4EALDH1A1MAPTHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025264954-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-12-26 — — WO disclosed
Send feedback